Oseltamivir (Tamiflu) Dosing
For adults and adolescents ≥13 years: 75 mg twice daily for 5 days for treatment, or 75 mg once daily for 10 days for prophylaxis. For children, dosing is weight-based, and treatment duration is 5 days for treatment and 10 days for prophylaxis 1, 2, 3.
Adult Dosing
Treatment:
- 75 mg orally twice daily for 5 days
- Initiate within 48 hours of symptom onset for maximum benefit 4, 1, 3
Prophylaxis:
- 75 mg once daily for at least 10 days following close contact exposure
- During community outbreak: 75 mg once daily for up to 6 weeks 1, 2, 3
Pediatric Dosing (≥12 months)
Weight-based dosing is preferred 4, 1, 2:
Treatment (twice daily for 5 days):
- ≤15 kg (≤33 lbs): 30 mg twice daily
15-23 kg (33-51 lbs): 45 mg twice daily
23-40 kg (51-88 lbs): 60 mg twice daily
40 kg (>88 lbs): 75 mg twice daily
Prophylaxis (once daily for 10 days):
Infants <12 Months
For infants 3-11 months:
The 2019 AAP guidelines provide more refined dosing for younger infants: 3.5 mg/kg twice daily for infants 9-11 months, and 3 mg/kg twice daily for term infants 0-8 months 1.
For infants <3 months:
- Treatment: 3 mg/kg/dose twice daily
- Prophylaxis: Not recommended unless situation judged critical due to limited safety data 4, 1
Critical caveat for premature infants: Standard dosing is NOT appropriate. Premature infants have immature renal function and require reduced doses based on postmenstrual age:
- <38 weeks: 1.0 mg/kg twice daily
- 38-40 weeks: 1.5 mg/kg twice daily
Renal Impairment
For creatinine clearance 10-30 mL/min 4, 1, 3:
- Treatment: 75 mg once daily for 5 days (reduced from twice daily)
- Prophylaxis: 30 mg once daily OR 75 mg every other day for 10 days
No dosing recommendations exist for patients on dialysis or with creatinine clearance <10 mL/min 3.
Administration Considerations
Can be taken with or without food, though administration with meals may improve gastrointestinal tolerability and reduce nausea/vomiting 4, 1, 3
Oral suspension concentration: The commercially available suspension is 6 mg/mL (changed from 12 mg/mL in earlier formulations) 1, 2
If suspension unavailable: Capsules can be opened and mixed with sweetened liquids (chocolate syrup, corn syrup, caramel topping, or light brown sugar dissolved in water) 4, 1, 3
For infants <1 year: Use an appropriate measuring device such as a 3-mL or 5-mL oral syringe instead of the standard dispenser 2
Treatment Duration Considerations
The standard 5-day treatment course is appropriate for most patients. However, immunocompromised patients may benefit from extended 10-day treatment to reduce viral rebound and resistance development 1, 5, 6. Recent evidence suggests that in immunocompromised patients, conventional dosing for 10 days may be preferable to double-dose regimens, as resistance rates were higher with conventional dosing but safety was better 5.
Common Pitfalls
Delayed initiation: Efficacy decreases significantly when treatment begins >48 hours after symptom onset. Treatment within 12 hours provides an additional 74.6 hours of symptom reduction compared to treatment at 48 hours 7.
Incorrect infant dosing: Do not use adult weight-based dosing for premature infants—they require substantially lower doses due to immature renal function 4, 1.
Prophylaxis duration: For institutional outbreaks, prophylaxis should continue for at least 14 days and for 7 days after the last known exposure 2.
Renal dosing oversight: Failure to adjust doses in renal impairment can lead to drug accumulation and toxicity 4, 3.
The most recent and comprehensive pediatric guidelines from 2024 2 and 2019 1 provide the most refined dosing recommendations, particularly for young infants and special populations, and should guide current practice alongside the FDA label 3.